Functional and clinical characteristics of focal adhesion kinases in cancer progression

Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase and an adaptor protein that primarily regulates adhesion signaling and cell migration. FAK promotes cell survival in response to stress. Increasing evidence has shown that at the pathological level, FAK is highly expressed in multiple tum...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in cell and developmental biology Vol. 10; p. 1040311
Main Authors Zhang, Zhaoyu, Li, Jinlong, Jiao, Simin, Han, Guangda, Zhu, Jiaming, Liu, Tianzhou
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 02.11.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase and an adaptor protein that primarily regulates adhesion signaling and cell migration. FAK promotes cell survival in response to stress. Increasing evidence has shown that at the pathological level, FAK is highly expressed in multiple tumors in several systems (including lung, liver, gastric, and colorectal cancers) and correlates with tumor aggressiveness and patient prognosis. At the molecular level, FAK promotes tumor progression mainly by altering survival signals, invasive capacity, epithelial-mesenchymal transition, the tumor microenvironment, the Warburg effect, and stemness of tumor cells. Many effective drugs have been developed based on the comprehensive role of FAK in tumor cells. In addition, its potential as a tumor marker cannot be ignored. Here, we discuss the pathological and pre-clinical evidence of the role of FAK in cancer development; we hope that these findings will assist in FAK-based clinical studies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
This article was submitted to Cell Adhesion and Migration, a section of the journal Frontiers in Cell and Developmental Biology
Reviewed by: Pranshu Sahgal, Dana–Farber Cancer Institute, United States
Edited by: Wassim Abou-Kheir, American University of Beirut, Lebanon
Keefe T. Chan, Peter MacCallum Cancer Centre, Australia
These author share first authorship
ISSN:2296-634X
2296-634X
DOI:10.3389/fcell.2022.1040311